Phospholipid Bilayer-Coated Aluminum Nanoparticles as an Effective Vaccine Adjuvant-Delivery System
Source abstract
Abstract
The phospholipid bilayer-coated aluminum nanoparticles (PLANs), formed via chemisorption, were prepared by reverse ethanol injection-lyophilization (REIL) utilizing the phosphophilicity of aluminum. The anhydrous antigen-loaded PLANs obtained by REIL proved stable, satisfying using the controlled-temperature-chain instead of the integrated cold-chain for distribution, and could be rehydrated to reconstitute instantly an aqueous suspension of the antigen-PLANs, which were more readily taken up by antigen-presenting cells and, when given subcutaneously to mice, induced more robust antigen-specific humoral and cellular immunoresponses but less local inflammation than the antigen-alum. Thus, the PLANs are a useful vaccine adjuvant-delivery system with advantages over the widely used naked alum.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Immune Response and Inflammation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Anhui Medical University, 81 Plum Hill Road, Hefei, Anhui Province 230032, China
School of Medical Engineering, Hefei University of Technology, 193 Tun Brook Road, Hefei, Anhui Province 230009, China
Funding
National Natural Science Foundation of China · Ministry of Education of the People's Republic of China · Anhui Medical University
References (29)
Show source-provided references
1. Ozawa S. · Vaccine · 2012 · 31 · 9610.1016/j.vaccine.2012.10.103 ↗
2. De Gregorio E. · Nat. Rev. Immunol. · 2014 · 14 · 50510.1038/nri3694 ↗
3. Moyle P. M. · ChemMedChem · 2013 · 8 · 36010.1002/cmdc.201200487 ↗
4. Reed S. G. · Nat. Med. · 2013 · 19 · 159710.1038/nm.3409 ↗
5. Pearton M. · Vaccine · 2010 · 28 · 610410.1016/j.vaccine.2010.05.055 ↗
6. Glenny A. · J. Pathol. · 1926 · 29 · 3110.1002/path.1700290106 ↗
7. Garcon N. · Expert Rev. Vaccines · 2007 · 6 · 72310.1586/14760584.6.5.723 ↗
8. Exley C. · Trends Immunol. · 2010 · 31 · 10310.1016/j.it.2009.12.009 ↗
9. Hornung V. · Nat. Immunol. · 2008 · 9 · 84710.1038/ni.1631 ↗
10. Leslie M. · Science · 2013 · 341 · 2610.1126/science.341.6141.26 ↗
11. Flach T. L. · Nat. Med. · 2011 · 17 · 47910.1038/nm.2306 ↗
12. Didierlaurent A. M. · J. Immunol. · 2009 · 183 · 618610.4049/jimmunol.0901474 ↗
13. Sun B. · ACS Nano · 2013 · 7 · 1083410.1021/nn404211j ↗
14. Li H. · Nat. Nanotechnol. · 2011 · 6 · 64510.1038/nnano.2011.153 ↗
15. Tseng Y. C. · Biomaterials · 2014 · 35 · 468810.1016/j.biomaterials.2014.02.030 ↗
16. Zhao Q. · Anal. Biochem. · 2001 · 295 · 7610.1006/abio.2001.5175 ↗
17. Wang F. · Small · 2014 · 10 · 392710.1002/smll.201400850 ↗
18. Hansen B. · Vaccine · 2009 · 27 · 88810.1016/j.vaccine.2008.11.078 ↗
19. Even-Or O. · Vaccine · 2011 · 29 · 247410.1016/j.vaccine.2011.01.009 ↗
20. Gentine P. · J. Liposome Res. · 2013 · 23 · 1110.3109/08982104.2012.717298 ↗
21. Zipursky S. · Vaccine · 2014 · 32 · 143110.1016/j.vaccine.2014.01.038 ↗
22. Wang N. · Eur. J. Pharm. Biopharm. · 2014 · 88 · 19410.1016/j.ejpb.2014.04.007 ↗
23. Zarif L. · Methods Enzymol. · 2005 · 391 · 31410.1016/S0076-6879(05)91018-5 ↗
24. Iyer S. · Vaccine · 2003 · 21 · 121910.1016/S0264-410X(02)00556-X ↗
25. Kendall D. A. · J. Biol. Chem. · 1982 · 257 · 1389210.1016/S0021-9258(19)45313-1 ↗
26. Li H. B. · Fresenius J. Anal. Chem. · 2000 · 368 · 50110.1007/s002160000478 ↗
27. Neutra M. R. · Nat. Rev. Immunol. · 2006 · 6 · 14810.1038/nri1777 ↗
28. Norman J. J. · Vaccine · 2014 · 32 · 185610.1016/j.vaccine.2014.01.076 ↗
29. Muraoka D. · ACS Nano · 2014 · 8 · 920910.1021/nn502975r ↗